Canlyniadau Chwilio - Neuwirth, Rachel

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours gan Moore, Kathleen N, Bauer, Todd M, Falchook, Gerald S, Chowdhury, Swapan, Patel, Chirag, Neuwirth, Rachel, Enke, Aaron, Zohren, Fabian, Patel, Manish R

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors gan Adjei, Alex A., LoRusso, Patricia, Ribas, Antoni, Sosman, Jeffrey A., Pavlick, Anna, Dy, Grace K., Zhou, Xiaofei, Gangolli, Esha, Kneissl, Michelle, Faucette, Stephanie, Neuwirth, Rachel, Bózon, Viviana

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy gan van Duin, Mark, Broyl, Annemiek, de Knegt, Yvonne, Goldschmidt, Hartmut, Richardson, Paul G., Hop, Wim C. J., van der Holt, Bronno, Joseph-Pietras, Debora, Mulligan, George, Neuwirth, Rachel, Sahota, Surinder S., Sonneveld, Pieter

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model‐Based Support for Body Surface Area‐Based Dosing Over the 2‐ to 16‐Year Age Range gan Hanley, Michael J., Mould, Diane R., Taylor, Timothy J., Gupta, Neeraj, Suryanarayan, Kaveri, Neuwirth, Rachel, Esseltine, Dixie‐Lee, Horton, Terzah M., Aplenc, Richard, Alonzo, Todd A., Lu, Xiaomin, Milton, Ashley, Venkatakrishnan, Karthik

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase 1 NCI Organ Dysfunction Working Group Study NCI-643... gan LoRusso, Patricia M, Venkatakrishnan, Karthik, Ramanathan, Ramesh K, Sarantopoulos, John, Mulkerin, Daniel, Shibata, Stephen I, Hamilton, Anne, Dowlati, Afshin, Mani, Sridhar, Rudek, Michelle A, Takimoto, Chris H, Neuwirth, Rachel, Esseltine, Dixie-Lee, Ivy, Percy

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma gan Reece, Donna E., Sullivan, Dan, Lonial, Sagar, Mohrbacher, Ann F., Chatta, Gurkamal, Shustik, Chaim, Burris, Howard, Venkatakrishnan, Karthik, Neuwirth, Rachel, Riordan, William J., Karol, Michael, von Moltke, Lisa L., Acharya, Milin, Zannikos, Peter, Stewart, A. Keith

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution gan Tang, Min, Zhao, Rui, van de Velde, Helgi, Tross, Jennifer G., Mitsiades, Constantine, Viselli, Suzanne, Neuwirth, Rachel, Esseltine, Dixie-Lee, Anderson, Kenneth, Ghobrial, Irene M., San Miguel, Jesús F., Richardson, Paul G., Tomasson, Michael H., Michor, Franziska

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer gan Voss, Martin H., Gordon, Michael S., Mita, Monica, Rini, Brian, Makker, Vicky, Macarulla, Teresa, Smith, David C., Cervantes, Andrés, Puzanov, Igor, Pili, Roberto, Wang, Ding, Jalal, Shadia, Pant, Shubham, Patel, Manish R., Neuwirth, Rachel l., Enke, Aaron, Shou, Yaping, Sedarati, Farhad, Faller, Douglas V., Burris, Howard A.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Dose-Escalating and Pharmacological Study of Bortezomib in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study gan Leal, Ticiana B., Remick, Scot C., Takimoto, Chris H., Ramanathan, Ramesh K., Davies, Angela, Egorin, Merrill J., Hamilton, Anne, LoRusso, Patricia A., Shibata, Stephen, Lenz, Heinz-Josef, Mier, James, Sarantopoulos, John, Mani, Sridhar, Wright, John J., Ivy, S. Percy, Neuwirth, Rachel, von Moltke, Lisa, Venkatakrishnan, Karthik, Mulkerin, Daniel

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy gan Mulligan, George, Lichter, David I., Di Bacco, Alessandra, Blakemore, Stephen J., Berger, Allison, Koenig, Erik, Bernard, Hugues, Trepicchio, William, Li, Bin, Neuwirth, Rachel, Chattopadhyay, Nibedita, Bolen, Joseph B., Dorner, Andrew J., van de Velde, Helgi, Ricci, Deborah, Jagannath, Sundar, Berenson, James R., Richardson, Paul G., Stadtmauer, Edward A., Orlowski, Robert Z., Lonial, Sagar, Anderson, Kenneth C., Sonneveld, Pieter, San Miguel, Jesús F., Esseltine, Dixie-Lee, Schu, Matthew

Cael y testun llawn Cael y testun llawn Cael y testun llawn